What it sells
Helping Plastic Surgeons Rebuild Fat
Business model breakdown
Buyer: who owns the budget?
UnverifiedPlastic and reconstructive surgeons and hospitals/surgery centers buying a surgical biomaterial (inferred).
Trigger: what makes them buy now?
Synthetic implants and fillers have side effects; existing biomaterials are costly allografts or short-lived synthetic placeholders; need to improve fat-grafting volume retention in breast and facial reconstruction.
Workflow: what inputs become what output?
Harvest fat by liposuction, mix with Fractomer matrix, inject as one slurry, matrix solidifies at body temperature into a porous scaffold that stabilizes and vascularizes the graft.
Economics: what it saves and how it charges
UnverifiedMedical device/biomaterial sold per procedure (inferred); pre-commercial, no financials stated.
Distribution: how it reaches customers
UnverifiedPre-commercial; accepted to MedTech Innovator 2025; would sell to surgeons via regulatory clearance (inferred).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.